SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001213900-23-060427
Filing Date
2023-07-28
Accepted
2023-07-28 07:55:51
Documents
1
Group Members
DAEWOONG PHARMACEUTICAL CO. LTD

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ea182519-13ddaewoong_aeon.htm SC 13D 66727
  Complete submission text file 0001213900-23-060427.txt   68375
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Subject) CIK: 0001837607 (see all company filings)

IRS No.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-92271 | Film No.: 231120241
SIC: 2834 Pharmaceutical Preparations

Mailing Address 244, GALMACHI-RO, JUNGWON-GU SEONGNAM-SI, GYEONGGI-DO M5 13211
Business Address 244, GALMACHI-RO, JUNGWON-GU SEONGNAM-SI, GYEONGGI-DO M5 13211 82-2-550-8800
Daewoong Co., Ltd (Filed by) CIK: 0001985493 (see all company filings)

IRS No.: 000000000 | State of Incorp.: M5 | Fiscal Year End: 1231
Type: SC 13D